Safety of TNF inhibitors in adolescents and children

Area of Science:

• Pediatric Rheumatology and Gastroenterology
• Pharmacology and Therapeutics
• Immunology

Background:

• Tumor necrosis factor (TNF) inhibitors are increasingly utilized in pediatric care for conditions such as Crohn's disease and juvenile idiopathic arthritis.
• While effective, the comprehensive safety profile of these agents in children remains incompletely understood.
• Adverse effects observed in adults, including infections, malignancies, and demyelinating disorders, raise concerns for pediatric populations.

Purpose of the Study:

• To review the use and pharmacology of TNF inhibitors in children.
• To summarize current safety data for etanercept, adalimumab, and infliximab in pediatric patients.
• To assess the known risks and benefits of TNF inhibitors for pediatric indications.

Main Methods:

• Review of existing literature on TNF inhibitor use in children.
• Analysis of safety data from clinical trials and case reports.
• Comparison of adverse event profiles between pediatric and adult populations.

Main Results:

• TNF inhibitors are associated with an increased risk of malignancy, particularly lymphoma, in children.
• Pediatric patients exhibit an elevated rate of infections, including rare and opportunistic types, similar to adults.
• Infusion or injection-site reactions occur, with infliximab showing a lower rate of infusion reactions in children compared to adults.

Conclusions:

• Due to limited long-term safety data, TNF inhibitors in children should be reserved for refractory cases.
• Thorough risk assessment and patient/parental understanding are crucial before initiating TNF inhibitor therapy.
• Ongoing monitoring is essential to fully elucidate the long-term safety of these agents in pediatric populations.